IRIS
IEZZI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.846
EU - Europa 1.516
AS - Asia 951
Continente sconosciuto - Info sul continente non disponibili 192
SA - Sud America 131
AF - Africa 18
OC - Oceania 1
Totale 4.655
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.813
RU - Federazione Russa 753
SG - Singapore 372
CN - Cina 257
IT - Italia 132
IE - Irlanda 129
VN - Vietnam 116
SE - Svezia 110
DE - Germania 101
BR - Brasile 87
FR - Francia 80
UA - Ucraina 75
TR - Turchia 73
GB - Regno Unito 56
IN - India 36
HK - Hong Kong 33
AR - Argentina 15
AT - Austria 15
FI - Finlandia 12
MX - Messico 12
CA - Canada 11
ES - Italia 11
CZ - Repubblica Ceca 10
BD - Bangladesh 9
IQ - Iraq 9
CO - Colombia 8
JP - Giappone 8
PL - Polonia 8
ZA - Sudafrica 7
PY - Paraguay 6
SA - Arabia Saudita 6
CL - Cile 5
RO - Romania 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
KE - Kenya 4
LB - Libano 4
LT - Lituania 4
NL - Olanda 4
UZ - Uzbekistan 4
VE - Venezuela 4
JO - Giordania 3
PH - Filippine 3
BO - Bolivia 2
EC - Ecuador 2
ET - Etiopia 2
GT - Guatemala 2
KR - Corea 2
OM - Oman 2
PK - Pakistan 2
PT - Portogallo 2
TN - Tunisia 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
LC - Santa Lucia 1
MA - Marocco 1
MQ - Martinica 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
VG - Isole Vergini Britanniche 1
Totale 4.463
Salva come PNG Salva come JPEG
Città #
Singapore 310
Chandler 238
San Jose 217
Ashburn 151
Dublin 128
Jacksonville 127
Los Angeles 106
Dearborn 90
Beijing 76
Dallas 59
Houston 59
Princeton 52
Munich 43
Izmir 41
Council Bluffs 39
Nanjing 39
Ho Chi Minh City 37
Hong Kong 32
Santa Clara 32
Wilmington 29
Chieti 28
New York 28
Altamura 26
The Dalles 25
Ann Arbor 21
Boardman 20
Dong Ket 20
Hanoi 18
Southend 16
Moscow 15
Orem 15
São Paulo 15
Cambridge 13
Kunming 13
London 12
Redondo Beach 12
Nanchang 10
Nuremberg 10
Washington 10
Atlanta 9
Brno 9
Chicago 9
Denver 9
Pescara 9
Shenyang 9
St Louis 9
Brooklyn 8
Buffalo 8
Frankfurt am Main 8
Stockholm 8
Vienna 8
Jiaxing 7
Montreal 7
Norwalk 7
Tokyo 7
Warsaw 7
Da Nang 6
Hefei 6
Mexico City 6
Tianjin 6
Boston 5
Hebei 5
Helsinki 5
Johannesburg 5
Mumbai 5
Brussels 4
Chennai 4
Haiphong 4
Hyderabad 4
Manchester 4
Phoenix 4
Poplar 4
San Francisco 4
Tongling 4
Woodbridge 4
Zhengzhou 4
Amman 3
Amsterdam 3
Asunción 3
Bogotá 3
Falls Church 3
Hangzhou 3
Istanbul 3
Joinville 3
Miami 3
Parma 3
Perego 3
Pune 3
Querétaro 3
Rio de Janeiro 3
Rome 3
Savigliano 3
Secaucus 3
Tappahannock 3
Tashkent 3
Addis Ababa 2
Baghdad 2
Cali 2
Campinas 2
Cerveteri 2
Totale 2.530
Salva come PNG Salva come JPEG
Nome #
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 928
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 189
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 179
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 173
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 173
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 165
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 161
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 157
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 151
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 149
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 141
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 140
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 140
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 138
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 135
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 134
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 130
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 129
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 128
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 128
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 128
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 126
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 125
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 119
Triple positive early breast cancer in the pre- and post Trastuzumab eras: a subgroup analysis of a multicenter retrospective study. 113
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting 99
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting 96
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 81
Totale 4.655
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.409
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022136 0 0 0 33 6 4 6 8 9 4 15 51
2022/2023561 38 75 38 77 48 100 22 55 69 7 21 11
2023/2024268 31 13 17 11 19 99 38 5 6 10 3 16
2024/2025458 30 67 63 27 10 42 17 24 48 36 46 48
2025/20262.056 99 42 109 161 157 96 292 69 790 121 81 39
2026/2027185 87 56 42 0 0 0 0 0 0 0 0 0
Totale 4.655